Frommer Can Defend Par In Rythmol Suit: Judge

Law360, New York (April 25, 2008, 12:00 AM EDT) -- Reliant Pharmaceuticals Inc. lost a bid on Thursday to disqualify Frommer Lawrence & Haug LLP from defending Par Pharmaceuticals Inc. in a patent lawsuit over Reliant's heart drug Rythmol SR on the grounds that Frommer Haug had worked with Reliant to acquire the disputed patent.

Reliant asked the U.S. District Court for the District of Delaware for the disqualification last September, saying that Frommer Lawrence helped Reliant acquire the patent on Rythmol SR from Abbott Laboratories in 2003.

Because of this conflict of interest, Reliant said,...
To view the full article, register now.